Alirocumab after Acute Coronary Syndrome

Nick S.R. Lan, Bu B. Yeap, P. Gerry Fegan

Research output: Contribution to journalLetter

1 Citation (Scopus)

Abstract

To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab could reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy. However, because less than 3% of these patients were receiving ezetimibe in addition to statin therapy, the trial might not support the use of alirocumab in similar patients in clinical practice. According to the latest guideline on the management of cholesterol,(2) ezetimibe should be added to statin therapy (given at the . . .

Original languageEnglish
Pages (from-to)2075-2076
Number of pages2
JournalThe New England Journal of Medicine
Volume380
Issue number21
DOIs
Publication statusPublished - 23 May 2019

Fingerprint Dive into the research topics of 'Alirocumab after Acute Coronary Syndrome'. Together they form a unique fingerprint.

Cite this